🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the fight against superbug strains of the pathogen, according to researchers.

An International Challenge

Cases of gonorrhoea are escalating globally, with figures suggesting over 82 million infections annually. Particularly high rates are reported in Africa and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Public health authorities are particularly alarmed about the increase in treatment-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Clearance

Zoliflodacin, marketed under the name a brand name, was cleared by the American regulatory agency in recent days for treating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers hope that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, also received approval in concurrent days. This treatment, which is employed against urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This authorization represents a significant shift in the therapy of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Data and Worldwide Availability

According to results released by a major medical journal, zoliflodacin successfully treated more than 90% of cases of the STI. This establishes an equal footing with the existing first-line therapy, which combines two antibiotics. The study enrolled nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the rights to license and sell the drug in a wide range of developing nations.

Clinicians directly involved have expressed positive views. Having a easy-to-administer therapy like this is hailed as a "revolutionary step" for public health efforts. This is viewed as crucial to alleviate the strain of the disease for patients and to prevent the spread of extremely resistant gonorrhoea around the world.